Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

As with all agents being explored in AML, there is interest in using FLT3 inhibitors in combination with chemotherapy, though discussion remains regarding sequencing. Faderl says he believes there is interest in both moving away from intensive chemotherapy for the treatment of AML and combining FLT3 inhibitors with lower-intensity therapies.

Videos

Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AML

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Faderl believes that immunotherapies represent the area that will see the greatest expansion in hematologic malignancies. There has been much activity in FLT3-positive AMLs with novel inhibitors in combination with standard chemotherapies, though there is not much data available yet. Novel leukemia stem cell markers are interesting on a conceptual basis, though they may or may not hold promise, Faderl says.

Faderl says there is not a specific novel therapy that is a particular highlight.

Stefan Faderl, MD

Articles

Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AML

Dr. Faderl Gives an Overview of Novel Therapies for AML